RANI

In October 2025, Rani Therapeutics announced a collaboration with Chugai Pharmaceutical Co. and a private placement, leading to a stock surge and extended cash runway. In November 2025, the company reported its Third Quarter financial results. In December 2025, Rani repaid all outstanding debt. In January 2026, Alireza Javadi was promoted to Chief Technical Officer. In March 2026, Jesper Høiland was appointed as Head of Strategy and the company reported its Fourth Quarter and Full Year 2025 financial results, with the stock rising despite missing EPS forecasts. In April 2026, Dr. Sara Kenkare-Mitra was appointed as Strategic Advisor. In May 2026, Rani announced preclinical data demonstrating successful oral delivery of semaglutide and bioequivalence of RT-114. In June 2025, Rani received a Nasdaq notice regarding non-compliance with the minimum bid price requirement.